Skip to main content
Journal cover image

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.

Publication ,  Journal Article
Tetef, M; Doroshow, J; Akman, S; Coluzzi, P; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G
Published in: Cancer Invest
1995

A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma. The median age was 58 years; performance status ranged from 50 to 100%. Of 15 evaluable patients, 1 (7%) had a partial response lasting 2.4 months; 8 (53%) had stable disease with a median duration of 5.7 months; and 6 (40%) had progressive disease with a median time to progression of 2.7 months. Median survival was 3.8 months. Treatment with 5-FU and calcium leucovorin was moderately well tolerated; 9% of the treatment courses were complicated by grade 3 or 4 hematological toxicity, and 10% of the courses were complicated by grade 3 or 4 gastrointestinal toxicity. Despite the efficacy of the combination of 5-FU and leucovorin in advanced colorectal cancer, our results document the general resistance of hepatocellular carcinoma to modulated 5-FU.

Published In

Cancer Invest

DOI

ISSN

0735-7907

Publication Date

1995

Volume

13

Issue

5

Start / End Page

460 / 463

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Liver Neoplasms
  • Leucovorin
  • Humans
  • Fluorouracil
  • Female
  • Carcinoma, Hepatocellular
  • Antineoplastic Combined Chemotherapy Protocols
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tetef, M., Doroshow, J., Akman, S., Coluzzi, P., Leong, L., Margolin, K., … Somlo, G. (1995). 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest, 13(5), 460–463. https://doi.org/10.3109/07357909509024907
Tetef, M., J. Doroshow, S. Akman, P. Coluzzi, L. Leong, K. Margolin, R. J. Morgan, J. Raschko, S. Shibata, and G. Somlo. “5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.Cancer Invest 13, no. 5 (1995): 460–63. https://doi.org/10.3109/07357909509024907.
Tetef M, Doroshow J, Akman S, Coluzzi P, Leong L, Margolin K, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest. 1995;13(5):460–3.
Tetef, M., et al. “5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.Cancer Invest, vol. 13, no. 5, 1995, pp. 460–63. Pubmed, doi:10.3109/07357909509024907.
Tetef M, Doroshow J, Akman S, Coluzzi P, Leong L, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest. 1995;13(5):460–463.
Journal cover image

Published In

Cancer Invest

DOI

ISSN

0735-7907

Publication Date

1995

Volume

13

Issue

5

Start / End Page

460 / 463

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Liver Neoplasms
  • Leucovorin
  • Humans
  • Fluorouracil
  • Female
  • Carcinoma, Hepatocellular
  • Antineoplastic Combined Chemotherapy Protocols